Shattuck Labs Announces Participation in Upcoming SVB Securities Global Biopharma Conference

Rhea-AI Summary

Shattuck Labs, Inc. (NASDAQ: STTK) has announced participation in the SVB Securities Global Biopharma Conference, scheduled for February 13-16, 2023. The company specializes in developing bi-functional fusion proteins aimed at treating cancer and autoimmune diseases. Its lead program, SL-172154, is currently in multiple Phase 1 trials, targeting CD47 immune checkpoints while activating the CD40 pathway. Additionally, Shattuck is advancing its GADLEN™ platform, designed to connect gamma delta T cells with tumor antigens. The company is focused on transparent investor communication and compliance with regulatory obligations.

Positive

• Participation in the SVB Securities Global Biopharma Conference for increased visibility.
• Lead program SL-172154 is in multiple Phase 1 trials, indicating progress in clinical development.
• Innovative approach with bi-functional fusion proteins targeting cancer and autoimmune diseases.

Negative

• No financial metrics or results provided to assess the current economic standing.

AUSTIN, TX & DURHAM, NC, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that company management will participate in the SVB Securities Global Biopharma Conference being held virtually February 13-16, 2023.

About Shattuck Labs, Inc.
Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules with a single therapeutic. The company’s lead SL-172154 (SIRPα-Fc-CD40L) program, which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in multiple Phase 1 trials. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

The Company intends to use the investor relations portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD.

Investor & Media Contact:
Conor Richardson
Vice President of Investor Relations
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com

FAQ

What is Shattuck Labs' lead program SL-172154?

SL-172154 is a bi-functional fusion protein program that blocks the CD47 immune checkpoint and activates the CD40 pathway, currently in multiple Phase 1 trials.

When is the SVB Securities Global Biopharma Conference?

The SVB Securities Global Biopharma Conference will take place virtually from February 13-16, 2023.

What is the ticker symbol for Shattuck Labs?

The ticker symbol for Shattuck Labs is STTK.

What platforms does Shattuck Labs utilize for treatment?

Shattuck Labs utilizes the ARC® platform for bi-functional fusion proteins and the GADLEN™ platform for connecting gamma delta T cells with tumor antigens.